金十图示：2025年05月23日（周五）美股热门股票行情一览（美股盘初） @ JIN10.COM 金十数据 | 一个交易工具 IINTU D.UU -0.13(-0.74%) +0.41(+0.78%) -0.29(-1.05%) 恩智浦半导体 AG 美国国际集团 Phillips 66 ND 457.23亿市值 481.26亿市值 468.79亿市值 190.50 81.34 112.18 -6.01(-3.06%) -0.80(-0.71%) -0.68(-0.83%) 斯伦贝谢 © Torget 塔吉特 0 本田汽车 426.25亿市值 455.38亿市值 428.15亿市值 94.23 33.48 29.42 -0.83(-0.87%) -0.10(-0.34%) -0.27(-0.80%) 福特汽车 淡水河谷 Yum! Brands Ford Inc 412.37亿市值 405.53亿市值 402.42亿市值 10.37 9.50 144.78 -0.07(-0.67%) -0.08(-0.84%) -0.72(-0.50%) 瓦莱罗能源 2 367.94亿中值 易趣 ebay 402.42亿市值 ...

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector [3][6]. Core Insights - A significant collaboration has been established between Sanofi and Pfizer regarding SSGJ-707 (PD-1/VEGF dual antibody), with an upfront payment exceeding $1.25 billion and potential total payments reaching $4.8 billion, including milestone payments and a double-digit percentage sales share [3][7]. - The Hang Seng Healthcare Index increased by 6.83%, outperforming the Hang Seng Index by 6.44 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Sanofi and Pfizer's collaboration on SSGJ-707 includes global development rights, with Sanofi receiving an upfront payment of $1.25 billion and potential total payments of up to $4.8 billion [3][7]. - Kelun Biotech's TROP2 ADC has received acceptance for a new indication application, targeting HR+ HER2- breast cancer patients [3][7]. - Innovent Biologics' CD19 monoclonal antibody has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma in China [3][7]. - The report highlights the approval of BMS's TYK2 inhibitor for a new indication and a collaboration between Roche and Orionis for small molecule drugs [4][8]. 2. Overseas Social Services - Ctrip's Q1 2025 revenue increased by 16% to 13.9 billion yuan, with a non-GAAP operating profit of 4 billion yuan, maintaining a profit margin of 29% [12]. - The report maintains a target price of 590 HKD for Ctrip, with a "Buy" rating [12]. 3. Overseas Education - The education index rose by 1.4%, outperforming the Hang Seng National Enterprises Index by 0.7 percentage points [16]. - The report suggests focusing on vocational education companies, particularly China Oriental Education, due to a rebound in training demand [18].

Core Insights - The company has signed a licensing agreement with Pfizer for the PD1×VEGF dual antibody SSGJ707, granting Pfizer global rights (excluding mainland China) for development, production, and commercialization, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [1] - The PD1×VEGF dual antibody market is validated, with significant clinical results from competitors enhancing expectations for IO dual antibodies as alternatives to PD1 [2] - The company is expected to achieve substantial revenue growth from its main business, with several late-stage clinical assets projected to generate significant sales [2] Company Developments - The upfront payment of $1.25 billion is the largest for a Chinese innovative drug license out, setting a new record [1] - The company retains a 30% stake in the SSGJ707 project, indicating a strong interest in its future success [1] - The company is positioned as a leader in the domestic autoimmune field, with robust R&D capabilities and a pipeline of clinical assets nearing commercialization [3] Financial Projections - Revenue forecasts for 2025-2027 are projected at 1.37 billion, 1.57 billion, and 1.94 billion yuan, respectively, with net profits expected to be 300 million, 333 million, and 416 million yuan [3] - The company is anticipated to commercialize its IL17 monoclonal antibody by 2025 and submit an NDA for its IL1β monoclonal antibody in the same year, targeting a market with limited competition [2][3]

消息面上，2025年美国临床肿瘤学会（ASCO）年会即将于5月30日至6月3日在美国芝加哥正式召开。 ASCO大会是全球肿瘤学领域规模最大、最具影响力的学术盛会之一。多家国产创新药企此前已经宣布 将在本月底的ASCO大会上披露多项旗下创新管线的重磅临床和研发数据，有望成为整个创新药产业的 短期最强催化。叠加三生制药与辉瑞的重磅合作和恒瑞医药港股上市，港股创新药板块短期不乏催化。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，5月23日最新市盈率仅为 27倍，不足两个月前的一半，当前布局性价比突出。 信达证券认为，创新药和AI医疗主题在降息降准预期提升的背景下，仍有望成为下一阶段的进攻方 向。创新药方面，2025年第二季度可能迎来医保谈判和医保丙类目录落地等事件催化，多个重要肿瘤药 临床会议也将在这一时期举行，为板块带来积极影响。商业化快速放量的创新药标的以及具备较高研发 亮点的创新药标的均值得关注。核药创新药因其高技术壁垒，同样具备投资潜力。 相关产品：港股创新药ETF（159567）、创新药ETF（159992） 5月23日，港股市场低开高走，港股创新药板块涨势居前。港股创新药指 ...

Core Viewpoint - The announcement highlights the upcoming presentation of the first human Phase 1 clinical study design for the novel targeted antibody-drug conjugate (ADC) MesoC2 (HBM9033/PF-08052666) at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, in collaboration with Pfizer [1] Group 1 - MesoC2 was initially developed by the company's wholly-owned subsidiary, Nona Bioscience, utilizing its proprietary Harbour Mice platform and integrated ADC platform, and was licensed to Pfizer through a global agreement in December 2023 [1] - The ADC is currently undergoing a Phase 1 open-label study targeting various advanced solid tumor patients [1] - Pfizer will present clinical research information at the ASCO annual meeting, including a study assessing the safety and tolerability of MesoC2 in advanced solid tumor patients, with the abstract number TPS3163 and poster number 475a [1] Group 2 - MesoC2 has demonstrated significant anti-tumor efficacy in in vitro tests and xenograft models, showing acceptable safety characteristics in cynomolgus monkeys [2] - The Phase 1 trial (NCT06466187) will be conducted with dose escalation, dose optimization, and cohort expansion, evaluating up to 365 patients for MesoC2's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy based on RECIST v1.1 criteria [2]

Group 1: Innovation in China - China has transitioned from a follower to a leader in innovation, playing an increasingly important role in global industrial transformation [1] - According to the 2024 Global Innovation Index, China ranks 11th globally, the only middle-income economy in the top 30, improving one position from 2023 [1] - Notable advancements include the B2-W robotic dog by Yushu Technology and BYD's world record in electric vehicle charging speed, showcasing China's technological prowess [1] Group 2: Pharmaceutical Industry Developments - Recently, 3SBio signed an exclusive licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707, valued at over $6 billion, with a record $1.25 billion upfront payment [2] - This agreement signifies a shift for Chinese innovative pharmaceutical companies from imitation to global leadership, enhancing industry collaboration models [2] - The trend of Chinese pharmaceutical companies utilizing the License-out model for global expansion is becoming prominent, with AstraZeneca's CEO warning that Europe is losing its leading position in pharmaceutical innovation to China [2] Group 3: International Collaborations - Chinese companies are increasingly engaging in international collaborations, as seen with Bai Li Tianheng's $8.4 billion licensing deal for an ADC drug with Bristol-Myers Squibb [3] - As of 2024, China completed 94 License-out transactions in innovative drugs, totaling $51.9 billion, a 26% year-on-year increase [3] - In the first quarter of 2025, there were 41 License-out transactions amounting to $36.93 billion, setting a new historical record for the same period [3] Group 4: Global Impact of Chinese Innovation - China's large population and unique disease spectrum make it an indispensable part of global pharmaceutical innovation [4] - Pfizer's collaboration with Guardant Health for liquid biopsy testing in China exemplifies the international partnerships driving clinical development and research [4] - The ongoing international cooperation is crucial for the globalization of Chinese pharmaceutical innovation, enhancing its international influence [4] Group 5: Future Outlook - The Chinese pharmaceutical industry is moving from "scale accumulation" to "value creation," with a focus on innovation and global competitiveness [5] - Continuous improvement in innovation quality and deepening international cooperation are leading to a new round of value reassessment in the industry [5] - Investors are encouraged to focus on innovative companies with global competitiveness to capitalize on the benefits of China's pharmaceutical globalization [5]

Core Viewpoint - The recent surge in the Hong Kong innovative drug sector, particularly for Xiansheng Pharmaceutical, is driven by favorable factors such as the cyclical resurgence of COVID-19 and record-breaking domestic innovative drug business development (BD) deals [1] Group 1: Stock Performance - Xiansheng Pharmaceutical's stock price has experienced a continuous rise since May 16, achieving a maximum increase of 28.33% by May 21, with a cumulative increase of nearly 50% year-to-date [1] - The stock has shown significant trading activity, with over 25 million shares traded on three consecutive days from May 19 to 21, indicating strong market interest [4] Group 2: Business Development Potential - The recent $60.5 billion BD deal between Innovent Biologics and Pfizer has spotlighted the potential of Chinese innovative drugs, with Xiansheng Pharmaceutical being a key player in this growth [2] - Xiansheng Pharmaceutical has developed multiple ADC (antibody-drug conjugate) candidates targeting various biomarkers, with products like SCR-A006 showing Best-in-Class potential [2] Group 3: International Expansion - Xiansheng Pharmaceutical has established a track record in international markets, with its first overseas deal for SIM0278 setting a record for domestic autoimmune drug BD at the time [3] - The company has secured a licensing agreement exceeding $1 billion for SIM0500 with AbbVie, currently undergoing clinical trials in the U.S. and China [3] Group 4: Innovation and R&D - The company has invested over 8.5 billion yuan in R&D over six years, developing over 60 innovative drug candidates across various therapeutic areas [5] - Three new drug molecules are in the NDA approval process, while four are in Phase III clinical trials, indicating a robust pipeline [5] - The anticipated launch of significant new drugs will further enhance the company's position in the global biopharmaceutical market [5]

金十图示：2025年05月22日（周四）美股热门股票行情一览（美股盘初） 5076.63亿市值 422.55亿市值 170.15亿市值 569.37 1192.90 102.62 -1.04(-1.00%) -0.17(-0.03%) -1.73(-0.15%) 甲骨文 强生 P&G 宝浩 3881.27亿市值 3680.75亿市值 4410.92亿市值 165.54 157.29 152.98 +0.12(+0.07%) +0.12(+0.07%) -0.20(-0.13%) 家得宝 美国银行 (eget 可口可乐 111 3645.63亿市值 3248.12亿市值 3095.23亿市值 366.79 71.91 43.13 -4.05(-1.09%) -0.13(-0.29%) +0.06(+0.08%) T-Mobile US Inc 赛富时 t | 联合健康 2735.29亿市值 2730.40亿市值 2706.82亿市值 240.90 300.99 282.12 +0.14(+0.06%) -1.99(-0.66%) -0.17(-0.06%) IBM Crop (%) 通用电气(US) cisco ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has authorized Pfizer for the global development, production, and commercialization rights of SSGJ-707 outside of mainland China, receiving a non-refundable upfront payment of $1.25 billion, the largest in China's BD history. The agreement also includes potential milestone payments of up to $4.8 billion and a double-digit percentage sales share based on product sales in authorized regions [7] - The company is expected to achieve a peak sales value of $8.5 billion for SSGJ-707, contributing approximately 35 billion RMB to market value based on a 20x PE after discounting. The domestic peak sales are projected at 5 billion RMB, contributing around 15 billion RMB to market value. The existing business is expected to generate over 2 billion RMB in profit, corresponding to a market value of 30 billion RMB [7] - The company has raised its net profit forecasts for 2025-2026 from 2.63 billion RMB and 2.87 billion RMB to 9.91 billion RMB and 4.47 billion RMB, respectively, with an expected net profit of 5.17 billion RMB in 2027 [7] Financial Projections - Total revenue projections for the company are as follows: - 2023A: 7,836 million RMB - 2024A: 9,108 million RMB (up 16.24% YoY) - 2025E: 19,229 million RMB (up 111.13% YoY) - 2026E: 13,174 million RMB (down 31.49% YoY) - 2027E: 14,885 million RMB (up 12.98% YoY) [1] - Net profit projections are as follows: - 2023A: 1,549 million RMB - 2024A: 2,090 million RMB (up 34.93% YoY) - 2025E: 9,908 million RMB (up 373.98% YoY) - 2026E: 4,474 million RMB (down 54.85% YoY) - 2027E: 5,169 million RMB (up 15.54% YoY) [1] - The latest diluted EPS projections are: - 2023A: 0.65 RMB - 2024A: 0.87 RMB - 2025E: 4.13 RMB - 2026E: 1.87 RMB - 2027E: 2.15 RMB [1]

Investment Rating - The report maintains a "Recommended" rating for the company [5][7]. Core Insights - The company has signed an agreement with Pfizer to exclusively grant rights for its innovative PD-1/VEGF bispecific antibody SSGJ-707, receiving an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [3][4]. - SSGJ-707 shows best-in-class potential with promising clinical data in treating non-small cell lung cancer (NSCLC) and has received breakthrough therapy designation from the National Medical Products Administration [4]. - The company has a robust pipeline with 30 products in development, several of which are nearing market application, indicating a fruitful period ahead for its innovation pipeline [4]. Financial Projections - The company expects total revenue of RMB 182.44 billion, RMB 127.52 billion, and RMB 147.31 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of RMB 85.75 billion, RMB 34.13 billion, and RMB 41.02 billion [5][6]. - Earnings per share (EPS) are projected to be RMB 3.57, RMB 1.42, and RMB 1.71 for the years 2025, 2026, and 2027 respectively [6][9]. Business Development - The company is expanding its commercial footprint through partnerships, having secured four collaborations in 2024, which will enhance its product portfolio and revenue growth [5][4]. - Core products are expected to continue stable growth in 2024, with ongoing expansion into new indications and formulations [5].